Traduction de «for the fiscal year ended » (Néerlandais → Français) :

This release contains forward-looking information about an agreement by Pfizer to acquire FoldRx, and about FoldRx’s product candidate tafamidis, its other clinical and preclinical development programs and its technology platform, including their potential benefits, that involves substantial risks and uncertainties. Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments. A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and in its reports on Form 10-Q and Form 8-K.
Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments.

A further list and description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2010 and in its reports on Form 10-Q and Form 8-K. # # # # #
A further list and description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2010 and in its reports on Form 10-Q and Form 8-K.

Bestand CAMPUNIT Velden: CODE_AGR, YEAR_REGISTR, PERIOD_REGISTR, CODE_CAMPUS, CODE_UNIT, S3_YEAR_START_UNIT, S3_MONTH_START_UNIT, S3_DAY_START_UNIT, S3_YEAR_END_UNIT, S3_MONTH_END_UNIT en S3_DAY_END_UNIT
Fichier CAMPUNIT Champs : CODE_AGR, YEAR_REGISTR, PERIOD_REGISTR, CODE_CAMPUS, CODE_UNIT, S3_YEAR_START_UNIT, S3_MONTH_START_UNIT, S3_DAY_START_UNIT, S3_YEAR_END_UNIT, S3_MONTH_END_UNIT et S3_DAY_END_UNIT

If Alcon’s year-end closing price had been the only measure used for the impairment test, the value of this investment would have been USD 6.6 billion, or approximately USD 3.8 billion below the year-end carrying value on the Novartis consolidated balance sheet.
Si le test de dépréciation avait été fait uniquement sur la base du cours de clôture de l’action Alcon en fin d’année, la valeur de cet investissement aurait été d'USD 6,6 milliards, soit environ USD 3,8 milliards de moins que sa valeur au bilan consolidé de Novartis en fin d'année.

The Group’s equity rose by USD 8.8 billion since the prior year-end to USD 66.2 billion at September 30, and includes the 23% Alcon additional non-controlling interests of USD 6.1 billion.
Les fonds propres du Groupe ont progressé d’USD 8,8 milliards depuis la fin de l’exercice précédent à USD 66,2 milliard au 30 septembre et comprennent les intérêts minoritaires de 23% d’Alcon s’élevant à USD 6,1 milliards.

The potential use of Zometa for adjuvant breast cancer in premenopausal women is being reviewed by US and European regulatory authorities with feedback anticipated by year end.
L’utilisation possible de Zometa en tant qu'adjuvant au traitement du cancer du sein chez les femmes préménopausées est actuellement examinée par les autorités réglementaires américaines et européennes dont un avis est attendu avant la fin de cette année.

Based on the limited access to Alcon the following accounting implications are estimates and will be finalized for the Novartis 2010 year-end reporting.
En raison de l’accès limité à Alcon, les implications comptables suivantes sont des estimations qui seront précisées dans les comptes de Novartis au quatrième trimestre 2010.

- At the end of the school year, a conference is organised in Brussels during which all participating students and patients meet in order to present their projects.
- A la fin de l’année scolaire, une conférence a lieu à Bruxelles, rassemblant tous les élèves et patients participants pour présenter leurs projets.

Research carried out with those bereaved by suicide has revealed that those who have put an end to their lives showed symptoms of psychiatric disorders in the months or years preceding their fatal suicide attempt:
Des études réalisées auprès de proches de décédés ont permis de mettre en évidence que les personnes ayant mis fin à leur jours ont connu, dans les mois ou années qui précédent leur tentative de suicide fatale, des symptômes de troubles psychiatriques tels que:

- At the end of the follow-up and potential referral, the suicidal individuals are contacted again by telephone (provided they have agreed to this) after a period of one month / three months / six months / a year, in order to maintain contact and assess their general evolution.
- au terme du suivi et de l’orientation éventuelle, un contact téléphonique est repris avec le suicidant (pour autant qu’il ait manifesté son accord) à l’échéance d’un mois / trois mois / six mois / un an afin de maintenir le lien et jauger l’évolution générale de la personne.